Treatment Sequencing Decisions for B-ALL: Perspectives From Moffitt Cancer Center

EP: 1.CAR T-cell Therapy for B-ALL

EP: 2.Navigating Treatment Selections for B-ALL: Insights From the Moffitt Cancer Center

EP: 3.The Multidisciplinary Approach to CAR T-Cell Therapy for B-ALL

EP: 4.CAR T-Cell Therapy for B-ALL: Roles Within the Multidisciplinary Care Team

EP: 5.Optimizing Molecular Profiling for B-ALL Treatment

EP: 6.Multidisciplinary Clinical Perspectives: Factors That Influence CAR T-Cell Sequencing in B-ALL

EP: 7.Considerations Regarding Bridging Therapy for B-ALL CAR T-Cell Treatment

EP: 8.Obe-Cel for B-ALL: Insights Regarding Persistence, Toxicity, and Remission

EP: 9.CAR T-Cell Therapy Decisions in B-ALL: The Role of Obe-Cel in B-ALL Treatment

EP: 10.Managing Immunotoxicities With CAR T-Cell Therapy for B-ALL

Now Viewing

EP: 11.Treatment Sequencing Decisions for B-ALL: Perspectives From Moffitt Cancer Center

EP: 12.Future Considerations for Treatment Sequencing in B-ALL

Video content above is prompted by the following:

From the perspective of coordination of care, what characteristics of patient, disease, and/or CAR T-cell construct are considered when determining if a patient achieving an MRD-negative CR post CAR T-cell therapy should proceed to consolidative SCT?

• Under which circumstances could CAR T-cell therapy be considered a standalone treatment?
• In your professional experience, what are the principal risk factors for relapsed disease and what are some feasible prevention or mitigation strategies?
• How does early T-cell exhaustion affect the decision to proceed with allo-HSCT in previous recipients of CAR T-cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL)?
• In addition to T-cell exhaustion, what other factors drive that decision?